Poly (ADP-ribose) polymerase inhibitors (PARPi) are a novel therapeutic option for the treatment of ovarian and breast cancers which preferentially target BRCA1-defective cells and spare those with normal function [111]. This evidence concerns the gene BRCA1 and breast carcinoma.